一项研究研究了不同批准的药物对身体如何处理研究的影响的研究,该研究更复杂RO7795081
一项开放标签的固定序列研究,以研究多种口服伊斯兰唑的多种口服剂量,多种口服吉菲布罗齐和单一口服剂量的环孢素对健康参与者的单一口服RO7795081的药代动力学的影响
This is a single-center, non-randomized, open-label, cross-over study in healthy male and female participants.
Part 1 of the study has a 2-period (a single fixed sequence) design and will investigate the impact of itraconazole on the pharmacokinetics (PK) of RO7795081 in healthy participants. A maximum of up to 25 participants will be enrolled in Part 1 and sequentially undergo Period 1 (RO7795081 alone) followed by Period 2 (RO7795081 with itraconazole).
Part 2 of the study has an adaptive design with up to 4 periods (a single fixed sequence) and will investigate the impact of gemfibrozil and cyclosporine on the PK of RO7795081 in healthy participants. A maximum of up to 25 participants will be enrolled in Part 2 and sequentially undergo Period 1 (RO7795081 alone) followed by Period 2 (RO7795081 with gemfibrozil), Period 3 (RO7795081 with cyclosporine 200 mg), and finally Period 4 (RO7795081 with cyclosporine ≤600 mg).
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Groningen、荷兰、9728 NZ
- ICON
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Healthy biological males or females, defined by absence of evidence of any active or chronic disease
- Ability to communicate with the Investigator
- Able and willing to attend the necessary visits to the study site
- Not under judicial supervision, guardianship, or curatorship
- Body mass index (BMI) of 18 to 32 kg/m^2 inclusive, and a body weight of ≥50 kilograms at screening
Exclusion Criteria:
- Any condition or disease detected during the medical interview/physical examination that would render the participant unsuitable for the study, place the participant at undue risk or interfere with the ability of the participant to complete the study in the opinion of the Investigator
- History or presence of any clinically significant cardiovascular, bronchopulmonary, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological, psychiatric, genitourinary, metabolic disorders, allergic diseases, cancer, or cirrhosis
- History or evidence of any medical condition capable of significantly altering the absorption, metabolism, or elimination of drugs
- Surgical history of the GI tract affecting gastric motility or altering the GI tract (with the exception of uncomplicated appendectomy and cholecystectomy)
- History of malignancy in the past 5 years, except for fully treated local basal carcinoma, or fully treated carcinoma in situ of cervix
- History of convulsions (other than benign febrile convulsions of childhood) including epilepsy, or personal history of significant cerebral trauma or central nervous system infections (e.g., meningitis)
- Any major illness (in the opinion of the Investigator) within 1 month before the screening examination or any febrile illness (in the opinion of the Investigator) within 1 week prior to screening and within 1 week prior to admission
- History of clinically significant hypersensitivity (e.g., drugs [including but not limited to lidocaine, caffeine, povidone-iodine], excipients) or clinically significant allergic reactions
- Have an abnormal blood pressure at the time of screening and on baseline, confirmed by the average of 3 blood pressure measurements, properly measured with well-maintained equipment: supine systolic blood pressure <90 millimetres of mercury (mmHg) or >140 mmHg or diastolic blood pressure <45 mmHg or >90 mmHg
- Confirmed (based on the average of ≥ 3 consecutive measurements) resting pulse rate greater than 100 or less than 40 beats per minute at the time of screening and on baseline
- History or presence during screening and baseline of clinically significant ECG abnormalities before study drug administration (e.g., PQ/PR interval >210 milliseconds (ms), QTcF >450 ms [>470 ms female participants], based on the average interval on triplicate ECGs) or cardiovascular disease (e.g., cardiac insufficiency, coronary artery disease, cardiomyopathy, congestive heart failure, family history of congenital long QT syndrome, family history of sudden death)
- Clinically significant abnormalities in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel, and urinalysis). In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility
- Any suspicion or history of alcohol abuse and/or suspicion of regular consumption of drug of abuse (including cannabis-containing products) and/or evidence of current or previous drug of abuse (including cannabis-containing products) dependency within 5 years before screening
- Participants who, in the Investigator's judgment, pose a suicidal or homicidal risk, or any participant with a history of suicidal or homicidal attempts
- Bipolar disorder, schizophrenia or any other serious psychiatric condition (e.g., Axis I Disorder, DSM-IV-TR)
- Uncontrolled behavioral symptoms incompatible with compliance or evaluability (e.g., severe agitation, lack of impulse control, violence, and severe dysphoria)
- Any other medical condition not previously mentioned that could be expected to progress, recur, or change to such an extent that it could bias the assessment of the clinical or mental status of the participant to a significant degree or put the participant at special risk
- Presence of any acute or chronic illness or history of chronic illness not otherwise mentioned elsewhere and sufficient to invalidate the participant's participation in the trial or make it unnecessarily hazardous. Such conditions may include clinically significantly impaired endocrine, thyroid, hepatic, respiratory or renal function for any reason, unstable diabetes mellitus and insulin-dependent diabetes mellitus, clinically significant cardiovascular disease, pheochromocytoma, or history of any psychotic mental illness
- Known active or uncontrolled bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds, including participants exhibiting symptoms consistent with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within 6 weeks prior to Period 1 Day 1
- Vaccination within 6 weeks prior to Period 1 Day 1, including influenza and/or SARS-CoV-2/COVID-19 vaccination
- Use of any prohibited medications and food before study start and during the study
- Participants likely to need concomitant medication during the study period, with some exceptions
- Participation in an investigational drug or device study within 90 days prior to dosing, as calculated from the day of follow-up from the previous study or within 30 days
- Participation in an investigational drug study involving any therapeutic monoclonal antibody, protein derived from a monoclonal antibody, immunoglobulin therapy, or vaccine (with the exception of approved SARS-CoV-2/ COVID-19 vaccination) within 6 months prior to dosing (unless it can be documented that the participant was randomized to placebo) as calculated from the day of last dosing from the previous study
- Positive test for drugs of abuse or alcohol
- Positive result on human immunodeficiency virus (HIV)1 and HIV2, hepatitis C virus, or hepatitis B surface antigen
- Any suspicion or history of regular alcohol consumption for 1 month before screening defined as ≥21 drinks per week for males and ≥14 drinks per week for females
- Smokers who smoke more than 5 cigarettes per day or equivalent amount of tobacco (including e-cigarettes/vapes) as determined by history, and unable or unwilling not to smoke during the in-clinic period
- Donated over 450 mL of blood or blood products or had significant blood loss within 3 months prior to screening
- Dietary restrictions that would prohibit the consumption of standardized meals
- History of hypersensitivity to itraconazole (or any other triazole antifungal agent), gemfibrozil, cyclosporine, or their formulation ingredients
- Inability or unwillingness to meet study requirements
- Predictable poor compliance or inability to communicate well with the Investigator
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:非随机化
- 介入模型:交叉作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part 1: RO7795081, Then RO7795081 and Itraconazole
In Part 1, Period 1 (8 days), participants will be administered a single oral dose of RO7795081 on Day 1. Washout period between Period 1 Day 1 and Period 2 Day -3: at least 7 days. In Part 1, Period 2 (26 days), participants will receive a 3-day lead-in oral administration of itraconazole (200 mg twice daily [BID] on Day -3 and 200 mg once daily [QD] on Day -2 and Day -1). On Day 1, a single oral dose of RO7795081 will be co-administered with itraconazole (200 mg QD), followed by continued itraconazole dosing (200 mg QD) from Day 2 up to and including Day 9. |
A single dose will be administered orally per study period (see arm descriptions).
其他名称:
Administered orally (see arm description). |
|
实验性的:Part 2: RO7795081, Then RO7795081 and Gemfibrozil, Then RO7795081 and Cyclosporine
In Part 2, Period 1 (8 days), participants will be administered a single oral dose of RO7795081 on Day 1. Washout period between Period 1 Day 1 and Period 2 Day -2: at least 7 days. In Part 2, Period 2 (10 days), participants will be co-administered a single oral dose of RO7795081 with gemfibrozil (600 mg BID) on Day 1, after a 2-day lead-in oral administration of gemfibrozil 600 mg BID (Day -2 to Day -1) followed by continued BID dosing up to and including Day 3. Washout period between Period 2 Day 1 and Period 3 Day 1: at least 7 days. In Part 2, Period 3 (8 days), participants will be co-administered a single oral dose of RO7795081 and a single oral dose of cyclosporine (200 mg) on Day 1. Washout period between Period 3 Day 1 and Period 4 Day 1: at least 7 additional days after Period 3 Day 7 (total of 14 days). In Part 2, Period 4 (18 days), participants will be co-administered a single oral dose of RO7795081 and a single oral dose of cyclosporine (600 mg or less) on Day 1. |
A single dose will be administered orally per study period (see arm descriptions).
其他名称:
Administered orally (see arm description). A single dose will be administered orally per study period (see arm descriptions). |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
第1部分:观察到的最大浓度(CMAX)RO7795081,单独管理并与伊曲康唑结合使用
大体时间:第1部分,周期1:第1至5天和第7天;第1部分,周期2:天-4,-1、1、1至10、12、14、20和26
|
第1部分,周期1:第1至5天和第7天;第1部分,周期2:天-4,-1、1、1至10、12、14、20和26
|
|
第1部分:观察到最大浓度(TMAX)RO7795081的时间,单独管理并与itraconazole结合
大体时间:第1部分,周期1:第1至5天和第7天;第1部分,周期2:天-4,-1、1、1至10、12、14、20和26
|
第1部分,周期1:第1至5天和第7天;第1部分,周期2:天-4,-1、1、1至10、12、14、20和26
|
|
第1部分:从时间0到最后一个可测量浓度(AUCLAST)RO7795081的面积曲线下的面积,单独管理并与Itraconazole结合使用
大体时间:第1部分,周期1:第1至5天和第7天;第1部分,周期2:天-4,-1、1、1至10、12、14、20和26
|
第1部分,周期1:第1至5天和第7天;第1部分,周期2:天-4,-1、1、1至10、12、14、20和26
|
|
第1部分:从时间0到RO7795081的浓度时间曲线下的区域,单独管理并与itraconazole结合使用
大体时间:第1部分,周期1:第1至5天和第7天;第1部分,周期2:天-4,-1、1、1至10、12、14、20和26
|
第1部分,周期1:第1至5天和第7天;第1部分,周期2:天-4,-1、1、1至10、12、14、20和26
|
|
第2部分:RO7795081的CMAX,单独管理并与Gemfibrozil或环孢菌素结合使用
大体时间:第2部分,第1:第1至5天和第7天;第2部分,周期2:天-3至5和7;第2部分,周期3:天-1至5和7;第2部分,周期4:天-1至5、7和18
|
第2部分,第1:第1至5天和第7天;第2部分,周期2:天-3至5和7;第2部分,周期3:天-1至5和7;第2部分,周期4:天-1至5、7和18
|
|
第2部分:RO7795081的TMAX,单独管理并与gemfibrozil或环孢菌素结合
大体时间:第2部分,第1:第1至5天和第7天;第2部分,周期2:天-3至5和7;第2部分,周期3:天-1至5和7;第2部分,周期4:天-1至5、7和18
|
第2部分,第1:第1至5天和第7天;第2部分,周期2:天-3至5和7;第2部分,周期3:天-1至5和7;第2部分,周期4:天-1至5、7和18
|
|
第2部分:RO7795081的Auclast,单独给药并与gemfibrozil或Cyclosporine结合使用
大体时间:第2部分,第1:第1至5天和第7天;第2部分,周期2:天-3至5和7;第2部分,周期3:天-1至5和7;第2部分,周期4:天-1至5、7和18
|
第2部分,第1:第1至5天和第7天;第2部分,周期2:天-3至5和7;第2部分,周期3:天-1至5和7;第2部分,周期4:天-1至5、7和18
|
|
第2部分:RO7795081的AUCINF,单独管理并与gemfibrozil或Cyclosporine结合使用
大体时间:第2部分,第1:第1至5天和第7天;第2部分,周期2:天-3至5和7;第2部分,周期3:天-1至5和7;第2部分,周期4:天-1至5、7和18
|
第2部分,第1:第1至5天和第7天;第2部分,周期2:天-3至5和7;第2部分,周期3:天-1至5和7;第2部分,周期4:天-1至5、7和18
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
第1部分:随着时间的推移,Itraconazole和羟基 - 依克罗唑的血浆浓度
大体时间:第1部分,周期2:天-3至2、4、6、8和14
|
第1部分,周期2:天-3至2、4、6、8和14
|
|
第2部分:随着时间的推移,吉菲布罗齐的血浆浓度
大体时间:第2部分,周期2:天-1至2和4
|
第2部分,周期2:天-1至2和4
|
|
第2部分:随着时间的推移,环孢菌素的血液浓度
大体时间:第2部分,第3:第1至5天和第7天;第2部分,第4:第1至5天和第7天
|
第2部分,第3:第1至5天和第7天;第2部分,第4:第1至5天和第7天
|
|
不良事件的发生率和严重性
大体时间:第1部分:从第一次学习治疗到安全随访(37天);第2部分:从第一次学习治疗到安全随访(56天)
|
第1部分:从第一次学习治疗到安全随访(37天);第2部分:从第一次学习治疗到安全随访(56天)
|
|
异常临床实验室测试结果的发生率
大体时间:第1部分:从第一次学习治疗到安全随访(37天);第2部分:从第一次学习治疗到安全随访(56天)
|
第1部分:从第一次学习治疗到安全随访(37天);第2部分:从第一次学习治疗到安全随访(56天)
|
|
异常生命体征的发生率
大体时间:第1部分:从第一次学习治疗到安全随访(37天);第2部分:从第一次学习治疗到安全随访(56天)
|
第1部分:从第一次学习治疗到安全随访(37天);第2部分:从第一次学习治疗到安全随访(56天)
|
|
心电图(ECG)参数异常的发生率
大体时间:第1部分:从第一次学习治疗到安全随访(37天);第2部分:从第一次学习治疗到安全随访(56天)
|
第1部分:从第一次学习治疗到安全随访(37天);第2部分:从第一次学习治疗到安全随访(56天)
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- BP45670
- 2024-517360-37-00 (注册表标识符:EU CT Number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.